Chinese Yam

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity energy

Research Overview

Recent research on Chinese yam (Dioscorea polystachya / D. opposita) has focused most heavily on its water-soluble polysaccharides: their extraction/purification, physicochemical characterization (e.g., UV/IR, GPC, 1D/2D NMR), and structure–function relationships. Multiple polysaccharide fractions have been described with differing molecular weights and architectures, including α-(1→4)-linked glucan backbones with branching and mannose-containing side chains (e.g., a low–molecular weight mannoglucan, CYP-1, branched at O-2/O-3/O-6). A second major theme is gastrointestinal fate and microbiome interaction: simulated digestion and fecal fermentation studies indicate relative resistance to upper-GI digestion, utilization by gut microbes during fermentation, and increased short-chain fatty acid production alongside shifts in specific taxa (e.g., increased Bifidobacterium; genus-level differences such as Bacteroides or Alistipes depending on preparation). Beyond human gut health, there is also applied nutrition work in animal production (broilers), and food safety surveillance identifying nontrivial mycotoxin occurrence in Chinese yam samples in market surveillance datasets.

The strongest evidence from the provided abstracts supports anti-inflammatory and barrier-protective effects of Chinese yam polysaccharides in preclinical models of intestinal inflammation. In DSS-induced colitis mice, Chinese yam polysaccharides (including defined fractions such as CYP-1) consistently improved clinical and histopathological outcomes and were associated with reduced pro-inflammatory mediators (e.g., TNF-α, IL-1β), increased anti-inflammatory IL-10, reduced MPO activity, and suppression of inflammatory signaling pathways (e.g., NF-κB and NLRP3 inflammasome). Several studies also converge on improved intestinal barrier integrity (upregulation of tight junction proteins such as ZO-1, occludin, claudin-1; increased mucin MUC-2) and downstream reductions in systemic endotoxin-related markers (e.g., LBP/ET) and oxidative stress indices. Mechanistically, the data support a model in which these polysaccharides act as microbiota-accessible carbohydrates that are fermented to beneficial metabolites (SCFAs) and reshape microbial communities, which in turn contributes to anti-inflammatory effects.

Key gaps include limited translation to humans: the evidence base is dominated by in vitro cell systems and mouse colitis models, with little direct clinical validation, dose–response characterization in humans, or standardized endpoints. Additional work is needed to reconcile heterogeneity across polysaccharide preparations (extraction methods, molecular weight distributions, branching patterns, and chemical substitutions) and to establish reproducible structure–activity relationships and quality-control markers suitable for functional food or therapeutic development. More rigorous causal microbiome studies (e.g., gnotobiotic models, metabolomics-linked mechanisms, and identification of active fermentation products) would strengthen mechanistic claims. Finally, broader agronomic and food-system research remains underdeveloped (as noted in the orphan-crop perspective), including cultivation/harvest constraints, breeding and propagation challenges, and systematic risk assessment/mitigation for contaminants such as mycotoxins in supply chains.

1. What conditions has Chinese Yam been studied for?

  • Inflammatory bowel disease models (especially ulcerative colitis/colitis): Multiple abstracts studied Chinese yam polysaccharides (CYP) or a purified fraction (CYP-1) in dextran sodium sulfate (DSS)-induced colitis in mice, and in LPS-stimulated intestinal/immune cell models.

  • Intestinal inflammation and barrier dysfunction (mechanistic models): CYP and “fermented CYP” were tested in LPS-stimulated coculture Caco-2/RAW264.7 cells, focusing on tight junctions and inflammatory mediators.

  • Obesity / lipid metabolism (animal model): One abstract describes CYP in high-fat diet (HFD)-fed obese mice, focusing on lipid metabolism regulation (details truncated in provided text).

  • Cancer-related contexts:

    • Colorectal cancer immunotherapy (preclinical): CYP was studied as an adjunct to anti–PD-1 therapy in MC38 and CT26 mouse tumor models.

    • In vitro tumor cell growth inhibition: One abstract reports CYP inhibiting BGC-823 cell growth (gastric cancer cell line) alongside antioxidant testing.

  • Antioxidant effects (in vitro and digestion models): CYP preparations (e.g., CYP-A) were evaluated for free-radical scavenging and how digestion changes molecular weight and antioxidant activity.

  • Gut microbiome modulation / prebiotic-like effects: Simulated digestion + fecal fermentation studies assessed SCFA production and changes in specific genera (e.g., Bifidobacterium, Megasphaera).

  • Animal production outcomes (broilers): Dietary CYP supplementation was studied for growth/carcass performance and antioxidant enzyme markers in chickens (not a human condition, but relevant to biological effects).

  • Food safety (contaminants): Chinese yam samples were included in a multi-mycotoxin survey; ~50% of Chinese yam batches tested positive for one or more mycotoxins in that dataset.

2. Does it work in treating those conditions? Summarize the evidence.

  • Colitis/UC (preclinical evidence: supportive, not definitive for humans):

    • In DSS-induced colitis mice, CYP (and Cyclocarya paliurus polysaccharide) improved colitis symptoms and shifted inflammatory markers: increased IL-10, decreased IL-1β and TNF-α, and reduced MPO activity (a neutrophil-associated inflammation marker). It also improved barrier-related proteins (MUC-2, ZO-1, occludin) and reduced serum markers linked to endotoxemia (LBP and endotoxin), with reported reductions in liver oxidative stress.

    • A purified fraction, CYP-1 (a mannoglucan, 2.86 kDa), inhibited pro-inflammatory cytokine overproduction in LPS-induced RAW264.7 cells and improved outcomes in DSS colitis mice, including reduced pathological damage, suppression of NF-κB and NLRP3 inflammasome signaling, restoration of junctional protein mRNA (e.g., ZO-1, claudin-1, occludin, connexin-43), and gut microbiota shifts (decreased Alistipes, Helicobacter, and an unidentified Enterobacteriaceae).

    • In an LPS-stimulated Caco-2/RAW264.7 coculture, fecal-fermented CYP showed greater anti-inflammatory effects and increased tight junction expression versus unfermented CYP, suggesting microbial transformation may enhance activity.

    • Limitations: These are animal and cell studies; the abstracts do not provide human clinical trial outcomes, dosing equivalence, or long-term safety in people with UC.

  • Obesity / lipid metabolism (preclinical, details limited in provided abstract):

    • The HFD obese mouse study indicates CYP was investigated for regulating lipid metabolism, but the provided text is truncated, so specific outcomes (e.g., weight, lipids, hepatic fat) cannot be confirmed from what was shared.

    • Limitations: Without the results section details, strength of evidence cannot be judged from the excerpt alone.

  • Colorectal cancer immunotherapy adjunct (preclinical evidence: promising, microbiota-dependent):

    • In MC38 and CT26 mouse models, CYP synergistically inhibited tumor growth when combined with anti–PD-1 monoclonal antibody. 16S rRNA data showed enrichment of certain “beneficial” taxa (e.g., Clostridia_UCG-014, Actinobacteria) and reduction of taxa described as pathogenic (e.g., Enterorhabdus, Desulfovibrionaceae).

    • Importantly, antibiotic ablation of gut microbiota abolished the benefit, supporting a microbiome-mediated mechanism.

    • Limitations: This is not evidence that Chinese yam treats cancer in humans; it suggests a hypothesis for adjunctive effects via microbiome modulation.

  • Antioxidant effects (in vitro; not direct evidence of clinical treatment):

    • CYP-A showed DPPH radical scavenging (~79% at 6 mg/mL) and digestion altered molecular weight and some antioxidant readouts (DPPH scavenging increased after intestinal digestion, while reducing power decreased).

    • Limitations: In vitro antioxidant assays do not reliably translate into clinical outcomes.

3. What health benefits does it have?

  • Gut anti-inflammatory and barrier-support effects (preclinical):

    • In DSS colitis models, CYP and/or CYP-1 improved inflammatory cytokine profiles (e.g., increased IL-10; decreased TNF-α, IL-1β), reduced MPO activity, and improved barrier markers (e.g., MUC-2, ZO-1, occludin; also claudin-1 and connexin-43 mRNA in the CYP-1 study).

    • Reduced serum markers associated with endotoxin exposure (LBP, endotoxin) were reported alongside improved intestinal integrity.

  • Prebiotic-like microbiome and metabolite effects:

    • During fecal fermentation, CYP led to increased short-chain fatty acids (SCFAs) and supported growth of Bifidobacterium and Megasphaera; released monosaccharides (glucose, mannose) were utilized by gut microbes.

    • Multiple studies report microbiota shifts with CYP/CYP-1 (e.g., changes in Bacteroides, Alistipes, Helicobacter, Enterobacteriaceae depending on preparation and model).

  • Antioxidant activity (mostly in vitro and animal biomarker contexts):

    • CYP preparations scavenged radicals (DPPH, hydroxyl, superoxide in one abstract) and digestion changed antioxidant profiles.

    • In broilers, dietary CYP (notably 500 mg/kg) increased serum antioxidant-related measures such as T-AOC, T-SOD, GPX, GST and improved some growth/carcass metrics.

  • Potential immunomodulatory/adjunct anticancer effects (preclinical):

    • CYP enhanced anti–PD-1 efficacy in mouse CRC models and altered the tumor microenvironment (e.g., reported inhibition of immunosuppressive M2 macrophages in the abstract excerpt).

  • Dietary fiber-like behavior (related yam polysaccharides):

    • Polysaccharides from Dioscorea opposita (DOP1/DOP2) were resistant to intestinal digestion in vitro and were suggested to function as dietary fiber; they also showed antioxidant activity and promoted intestinal peristalsis in zebrafish larvae at 500 μg/mL. (Note: these are yam polysaccharides from a related preparation; not necessarily identical to the CYP fractions in the colitis studies.)

4. Does it have any downsides or side effects?

  • Human side effects are not established in the provided abstracts: The abstracts focus on mechanistic, animal, and in vitro studies; they do not report adverse event rates in humans.

  • Food safety concern: mycotoxin contamination risk in real-world samples:

    • In a survey of 103 batches of starch-rich “medicinal foods,” Chinese yam had a 50% positivity rate for one or more mycotoxins (method: UFLC-MS/MS). This does not prove harm from yam itself, but it highlights that sourcing, storage, and quality control matter for consumer safety.

  • Potential for variable effects depending on preparation and fermentation:

    • Different CYP fractions have different structures and molecular weights (e.g., CYP-1 at 2.86 kDa; other CYP preparations reported at much higher molecular weights). The fermentation study suggests “fermented CYP” can have stronger anti-inflammatory effects than unfermented CYP in a cell model, implying that product form could change biological effects.

  • General caution (not directly evidenced here): As with other fermentable polysaccharides, some individuals may experience GI symptoms (gas, bloating) when increasing fermentable fibers, but this is not specifically reported in the provided abstracts.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (e.g., effects modified by human genetic variants in drug-metabolizing enzymes, immune genes, or transporters). Most effects described are microbiome- and inflammation-pathway related (e.g., NF-κB, NLRP3), but no genotype-stratified results are presented.

  • What can be said from the abstracts: The anti–PD-1 synergy study explicitly supports a microbiota-dependent mechanism (antibiotics abolished benefit), which suggests inter-individual variability may be driven more by microbiome composition than by known host pharmacogenomic variants—at least based on the evidence shown.

  • Evidence gap: No data here link Chinese yam or its polysaccharides to specific genetic polymorphisms (beneficial or harmful).

References

  1. Extraction, structural analysis, derivatization and antioxidant activity of polysaccharide from Chinese yam.
    Shiyang Zhou, Gangliang Huang, Guangying Chen (2021) - Food chemistry
  2. Alleviative effects of natural plant polysaccharides against DSS-induced ulcerative colitis via inhibiting inflammation and modulating gut microbiota.
    Hanyu Lu, Mingyue Shen, Yi Chen, Qiang Yu, Ting Chen, Jianhua Xie (2023) - Food research international (Ottawa, Ont.)
  3. Gut microbial fermentation promotes the intestinal anti-inflammatory activity of Chinese yam polysaccharides.
    Yajuan Bai, Yue Zhou, Ruifen Zhang, Yanxia Chen, Fengzhong Wang, Mingwei Zhang (2023) - Food chemistry
  4. Effect of
    Zichao Wang, Yi Zheng, Ziru Lai, Zhihao Kong, Xilei Hu, Peiyao Zhang, Yahui Yang, Na Li (2025) - Foods (Basel, Switzerland)
  5. Structural characteristics of a mannoglucan isolated from Chinese yam and its treatment effects against gut microbiota dysbiosis and DSS-induced colitis in mice.
    Pan Li, Nan Xiao, Liping Zeng, Jie Xiao, Jianzhao Huang, Yanan Xu, Yanlan Chen, Yunhong Ren, Bing Du (2020) - Carbohydrate polymers
  6. A Frontier Review of Nutraceutical Chinese Yam.
    Matthew Khol, Fanyi Ma, Lijing Lei, Wei Liu, Xiuhua Liu (2024) - Foods (Basel, Switzerland)
  7. Multi-mycotoxin detection and human exposure risk assessment in medicinal foods.
    Xiaofang Liao, Ying Li, Nan Long, Qingbin Xu, Peng Li, Jiabo Wang, Lidong Zhou, Weijun Kong (2023) - Food research international (Ottawa, Ont.)
  8. The structural characterization of a novel Chinese yam polysaccharide and its hypolipidemic activity in HFD-induced obese C57BL/6J mice.
    Xiaojuan Feng, Mingzhu Guo, Jingyao Li, Zhanyu Shen, Fanghua Mo, Yutong Tian, Binghui Wang, Chunling Wang (2024) - International journal of biological macromolecules
  9. Isolation, Characterization and Antioxidant Activity of Yam Polysaccharides.
    Zhedong Li, Wenhao Xiao, Jianhua Xie, Yi Chen, Qiang Yu, Weidong Zhang, Mingyue Shen (2022) - Foods (Basel, Switzerland)
  10. An underutilized orphan tuber crop-Chinese yam : a review.
    Janina Epping, Natalie Laibach (2020) - Planta
  11. Effects of Dietary Supplementation of Chinese Yam Polysaccharide on Carcass Composition, Meat Quality, and Antioxidant Capacity in Broilers.
    Yadi Chang, Jinzhou Zhang, Yan Jin, Jiahua Deng, Mingyan Shi, Zhiguo Miao (2023) - Animals : an open access journal from MDPI
  12. Characterization, in vitro digestibility, antioxidant activity and intestinal peristalsis in zebrafish of Dioscorea opposita polysaccharides.
    Ruijiao Wang, Wei Liu, Lu Liu, Fanyi Ma, Qian Li, Peng Zhao, Wenjing Ma, Juan Cen, Xiuhua Liu (2023) - International journal of biological macromolecules
  13. Chinese yam polysaccharide enhances anti-PD-1 immunotherapy in colorectal cancer through alterations in the gut microbiota and metabolites.
    Guangtao Zhang, Jiashu Pan, Xiangyuan Xu, Shuchang Nie, Lu Lu, Yanhua Jing, Fan Yang, Guang Ji, Hanchen Xu (2025) - International journal of biological macromolecules
  14. Characterization of gallic acid-Chinese yam starch biodegradable film incorporated with chitosan for potential use in pork preservation.
    Liyuan Rong, Xiaoyao Ji, Mingyue Shen, Xianxiang Chen, Xing Qi, Yulin Li, Jianhua Xie (2023) - Food research international (Ottawa, Ont.)
  15. Effect of in vitro simulated gastrointestinal digestion on the antioxidant activity, molecular weight, and microstructure of polysaccharides from Chinese yam.
    Xiaojuan Feng, Nana Bie, Jingyao Li, Mengli Zhang, Yihua Feng, Tingting Ding, Yue Zhao, Chunling Wang (2022) - International journal of biological macromolecules
  16. Optimization of the ultrafiltration-assisted extraction of Chinese yam polysaccharide using response surface methodology and its biological activity.
    Heng-Yue Xue, Jing-Ru Li, Yan-Geng Liu, Qi Gao, Xiao-Wen Wang, Jun-Wei Zhang, Masaru Tanokura, You-Lin Xue (2019) - International journal of biological macromolecules
  17. Effect of lactobacteria fermentation on structure and physicochemical properties of Chinese yam starch (Dioscorea opposita Thunb.).
    Meijuan Xu, Jian Zou, Xiaodong Zhao, Yongting Feng, Ruoyu Duan, Bao Yang (2022) - Food chemistry
  18. Chinese yam (Dioscorea opposita Thunb.) alleviates antibiotic-associated diarrhea, modifies intestinal microbiota, and increases the level of short-chain fatty acids in mice.
    Nan Zhang, Tisong Liang, Quan Jin, Cai Shen, Yifan Zhang, Pu Jing (2019) - Food research international (Ottawa, Ont.)
  19. Sulfated Chinese Yam Polysaccharides Alleviate LPS-Induced Acute Inflammation in Mice through Modulating Intestinal Microbiota.
    Shihua Wu, Xianxiang Chen, Ruixin Cai, Xiaodie Chen, Jian Zhang, Jianhua Xie, Mingyue Shen (2023) - Foods (Basel, Switzerland)
  20. Quantitative
    Xiaowan Huang, Yanli Wang, Wei Wang, Xiao Zhang, Lei Jiang, Jian Liu, Shuangyan Liu, Keqing Li, Chengping Xie, Qiang Wang (2023) - Analytical sciences : the international journal of the Japan Society for Analytical Chemistry


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!